Market cap
$12,568 Mln
Recently Viewed
Clear AllMarket cap
$12,568 Mln
Revenue (TTM)
$788 Mln
P/E Ratio
78.8
P/B Ratio
18.4
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$29 Mln
ROE
0.2 %
ROCE
-- %
Industry P/E
53.55
EV/EBITDA
63
Debt to Equity
1
Book Value
$--
EPS
$4.3
Face value
--
Shares outstanding
37,543,500
CFO
$137.72 Mln
EBITDA
$107.48 Mln
Net Profit
$165.61 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Shockwave Medical Inc (SWAV)
| 75.7 | 1.6 | 27.5 | 21.2 | 23.0 | 40.4 | -- |
|
BSE Sensex*
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Midcap 400#
| 8.8 | 8.4 | 4.4 | 29.6 | 13.4 | 5.8 | 9.4 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|
|
Shockwave Medical Inc (SWAV)
| -7.3 | 15.3 | 71.9 | 136.2 |
|
S&P Midcap 400
| 14.4 | -14.5 | 23.2 | 11.8 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United... States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California. As of May 31, 2024, Shockwave Medical, Inc. operates as a subsidiary of Johnson & Johnson. Read more
President, CEO & Director
Mr. Douglas E. Godshall M.B.A.
President, CEO & Director
Mr. Douglas E. Godshall M.B.A.
Headquarters
Santa Clara, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Shockwave Medical Inc (SWAV) is $334.75 (NASDAQ) as of 31-May-2024 09:30 EDT. Shockwave Medical Inc (SWAV) has given a return of 23% in the last 3 years.
The P/E ratio of Shockwave Medical Inc (SWAV) is 78.76 times as on 11-Jun-2024, a 47 premium to its peers’ median range of 53.55 times.
The P/B ratio of Shockwave Medical Inc (SWAV) is 18.38 times as on 11-Jun-2024, a 462 premium to its peers’ median range of 3.27 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
49.17
|
10.83
|
|
2022
|
36.17
|
15.28
|
|
2021
|
-683.18
|
25.81
|
|
2020
|
-52.10
|
15.17
|
|
2019
|
-20.62
|
5.47
|
The 52-week high and low of Shockwave Medical Inc (SWAV) are Rs -- and Rs -- as of 25-Apr-2026.
Shockwave Medical Inc (SWAV) has a market capitalisation of $ 12,568 Mln as on 11-Jun-2024. As per SEBI classification, it is a Mid Cap company.
Before investing in Shockwave Medical Inc (SWAV), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.